Somewhat Favorable News Coverage Somewhat Unlikely to Impact Sinovac Biotech (NASDAQ:SVA) Share Price

Media stories about Sinovac Biotech (NASDAQ:SVA) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sinovac Biotech earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.1988612620084 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Sinovac Biotech (NASDAQ:SVA) traded up $0.05 during mid-day trading on Tuesday, hitting $7.22. 153,500 shares of the stock traded hands, compared to its average volume of 123,010. Sinovac Biotech has a 12-month low of $4.60 and a 12-month high of $7.32.

Separately, BidaskClub downgraded shares of Sinovac Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, September 9th.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Sinovac Biotech (NASDAQ:SVA) Share Price” was published by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://weekherald.com/2017/11/14/sinovac-biotech-sva-receives-daily-news-sentiment-score-of-0-09.html.

Sinovac Biotech Company Profile

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

Insider Buying and Selling by Quarter for Sinovac Biotech (NASDAQ:SVA)

Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply